Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

03.22.2022

– Goldfinch Bio management to review recently announced positive preliminary data from TRACTION-2, ongoing Phase 2 trial evaluating GFB-887 in patients with FSGS –
 

— Guest speaker Katherine Tuttle, M.D., FASN, FACP, FNKF, Executive Director for Research at Providence Health Care and Professor of Medicines at the University of Washington to provide overview of FSGS —
 

— Event to be held Tuesday, March 29, 2022 at 4:00 p.m. ET —
 

CAMBRIDGE, Mass. – March 22, 2022 – Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will host a virtual event to discuss the unmet need in focal segmental glomerular sclerosis (FSGS), as well as the recently announced clinical data from TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 as a precision medicine for the treatment of FSGS. GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5). The event will be held on Wednesday, March 29, 2022, beginning at 4:00 p.m. ET.

Speakers:

• Katherine Tuttle, M.D., FASN, FACP, FNKF, Executive Director for Research at Providence Health Care, Professor of Medicine at the University of Washington and an investigator in the Phase 2 clinical trial of GFB-887, will provide an overview of FSGS and the current treatment paradigm, as well as progress toward advancing precision-based approaches to address the heterogeneity of FSGS and other chronic kidney diseases.

• Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio will review recently announced positive preliminary data from the company’s ongoing Phase 2 clinical trial evaluating GFB-887 in patients with FSGS. The data showed that FSGS patients treated with GFB-887 experienced a statistically significant and clinically meaningful 32% placebo-adjusted mean reduction in urine protein creatinine ratio (UPCR), a measure of proteinuria, at the end of 12 weeks of treatment (p=0.04). Additionally, the findings suggest the emergence of a precision medicine-driven patient selection strategy based on preliminary exploratory biomarker and genetic data.

A live webcast of the event will be available under “Videos & Features” on the company’s website at www.goldfinchbio.com. A replay of the webcast will be available on the Goldfinch Bio website following the event.

 

About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover, validate and drug novel targets that may allow us to better treat subsets of patients, within a heterogeneous kidney disease, based on common characteristics. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. Visit us at www.goldfinchbio.com to learn more.

Goldfinch Bio Contacts:

Investors: Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media: Liz Melone
lmelone@goldfinchbio.com